Bortezomib, commercially known as Velcade, is a proteasome inhibitor used primarily for the treatment of multiple myeloma and certain types of lymphoma. It was the first therapeutic proteasome inhibitor to be tested and approved for use in humans, marking a significant advancement in cancer therapy. By inhibiting the proteasome, bortezomib disrupts numerous cellular processes, leading to cancer cell death.
